A solid cannabinoid composition comprising: • (i) 0.3-10 wt.% of one or more cannabinoids; • (ii) 4-69 wt.% of one or more non-ionic surfactants with an HLB value of 10-25; and • (iii) at least 20 wt.% of one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose; • (iv) 0-5 wt.% water; wherein the combination of the one or more non-ionic surfactants and the one or more carbohydrates constitutes at least 70 wt.% of the composition. A sterile aqueous liquid for use in medical treatment, said liquid comprising: (a) 0.1 - 10 mg/mL of one or more cannabinoids; (b) one or more non-ionic surfactants with an HLB value of 10-25; (c) one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose; and (d) at least 85 wt.% water; wherein the one or more non-ionic surfactants and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3:1 to 30:1 and wherein the one or more carbohydrates and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3:1 to 300:1.
One aspect of the invention relates to a biocompatible medical product comprising at least 1% by weight of dry matter of a covalently cross-linked polymer that is obtained by reacting a nucleophilically activated polyoxazoline (NU-POX) with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU- POX comprising m nucleophilic groups; and said electrophiliccross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m≥2, n≥2 and m+n ≥5; and wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate. Also provided is a kit for producing the aforementionedbiocompatible cross-linked polymer. The biocompatible cross-linked polymers according to the invention have excellent implant and/or sealing characteristics.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 31/14 - Materials characterised by their function or physical properties
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
3.
Sterile alginate-based aqueous composition for medical use and process for the preparation thereof
7 mono- or dicarboxylates that are optionally substituted with up to 2 hydroxyl groups.
The alginate-based composition of the present invention has excellent storage stability and is easy to manufacture. The alginate-based aqueous compositions of the present invention can advantageously be used, for instance, to prevent adhesions between a healing trauma site and adjacent surrounding tissue. These compositions can further be used in implants or in pharmaceutical preparations for oral administration.
The present invention relates to ready-to-use sterile, alginate-based, aqueous compositions for medical use. More particularly, the invention relates to an aqueous composition for medical use that has been sterilized by heat sterilization and having a viscosity at 25 °C of at least 300 cP (Helipath® T F spindle, 100 rpm at 25 °C), said composition having a pH in the range of 6.5-7.5; containing 0.5-10 wt.% of an alginate salt; and further containing 10-500 mM of one or more dissolved C8-C12 fatty acid salts. The alginate-based composition of the present invention has excellent storage stability and is easy to manufacture. The alginate-based aqueous compositions of the present invention can advantageously be used, for instance, to prevent adhesions between a healing trauma site and adjacent surrounding tissue. These compositions can further be used in implants or in pharmaceutical preparations for oral administration.
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of polyoxazoline having a molar mass of at least 5 40,000 g/mol. The drug delivery systems of the present invention offer the advantage that the bioactive agent is readily released when the drug delivery system is contacted with water. The drug delivery system can be in the form of a solid dispersion, a mucoadhesive sheet, a tablet, a powder, a capsule.
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
6.
CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE
One aspect of the invention relates to a biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent, said electrophilically activated POX comprising m electrophilic groups; and said nucleophilic cross-linking agent comprising n nucleophilic groups, wherein the m electrophilic groups are capable of reaction with the n nucleophilic groups to form covalent bonds; wherein m≥2, n≥2 and m+n ≥5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m≥3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. The invention further relates to biocompatible medical products comprising such a cross-linked POX-polymer. Also provided is a kit for producing a biocompatible, cross-linked POX-polymer. The invention further provides a tissue adhesive medical product comprising at least 1% by weight of dry matter of EL-POX, said EL-POX comprising at least 2 electrophilic groups, including at least one pendant electrophilic group. The polymers according to the invention have excellent implant and/or sealing characteristics.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 31/14 - Materials characterised by their function or physical properties
The present invention relates to ready-to-use sterile, alginate-based, aqueous compositions for medical use. More particularly, the invention relates to an aqueous composition for medical use that has been sterilized by heat sterilization and having a viscosity at 25 ºC of at least 300 cP (Helipath® T F spindle, 100 rpmat 25 °C), said composition having a pH in the range of 6.5-7.5; containing 0.5-10 wt.% of an alginate salt; and further containing 10-500 mM of one or more dissolved C2 -C7 mono-or dicarboxylates that are optionally substituted with up to 2 hydroxyl groups. The alginate-based composition of the present invention has excellent storage stability and is easy to manufacture. The alginate-based aqueous compositions of the present invention can advantageously be used, for instance, to prevent adhesions between a healing trauma site and adjacent surrounding tissue. These compositions can further be used in implants or in pharmaceutical preparations for oral administration.
The present invention relates to a method for removing impurities from biopolymer material, e.g. polysaccharides, polypeptides or polynucleotides. More particularly, the present invention provides a method of reducing lipopolysaccharide levels in a lipopolysaccharide containing biopolymer material, comprising the successive steps of: a) providing an aqueous solution containing 0.05-50 wt. % of dissolved lipopolysaccharide-containing biopolymer material; 0.001-10 wt.% of a surfactant; 0.05-15 wt. % of solid adsorbent; and at least 50 wt. % of water; b) allowing the adsorbent to adsorb lipopolysaccharides; c) separating the solid adsorbent containing adsorbed lipopolysaccharides from the remaining aqueous solution; and d) recovering the biopolymer material containing a reduced level of lipopolysaccharide from the separated aqueous solution.
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of polyoxazoline having a molar mass of at least 5 40,000 g/mol. The drug delivery systems of the present invention offer the advantage that the bioactive agent is readily released when the drug delivery system is contacted with water. The drug delivery system can be in the form of a solid dispersion, a mucoadhesive sheet, a tablet, a powder, a capsule.
The present invention relates to a dispensing system that can be used to introduce a gel-forming fluid into or onto the body that will produce a homogeneous gel in situ. The system according to the present invention comprises: a first reservoir comprising a first flowable composition in the form of an aqueous solution of ionically cross-linkable alginate; a second reservoir comprising a second flowable composition, said second flowable composition containing one or more polyols; a first outlet from the first reservoir; a second outlet from the second reservoir, said first outlet and said second outlet being arranged in such a way that the first flowable composition is mixed with the second flowable composition when both compositions are simultaneously expelled from the respective reservoirs thereby forming the gel- forming fluid; wherein the first and/or second flowabel composition contains a cross- linking agent and upon admixture of the first flowable composition with the second flowable composition said cross-linking agent initiates the formation of a solid or semi-solid ionically cross- linked alginate gel. The presence of a substantial amount of polyol in the second flowable composition favourably affects the cross-linking reaction between the cross-linking agent and the alginate.
A61F 2/46 - Special tools for implanting artificial joints
B01F 11/00 - Mixers with shaking, oscillating, or vibrating mechanisms
B01F 13/00 - Other mixers; Mixing plant, including combinations of dissimilar mixers
B05C 17/005 - Hand tools or apparatus using hand-held tools, for applying liquids or other fluent materials to, for spreading applied liquids or other fluent materials on, or for partially removing applied liquids or other fluent materials from, surfaces for discharging material through an outlet orifice by pressure
A61K 9/00 - Medicinal preparations characterised by special physical form
11.
METHOD FOR REMOVING IMPURITIES FROM BIOPOLYMER MATERIAL
The present invention relates to a method for removing impurities from biopolymer material, e.g. polysaccharides, polypeptides or polynucleotides. More particularly, the present invention provides a method of reducing lipopolysaccharide levels in a lipopolysaccharide containing biopolymer material, comprising the successive steps of: a) providing an aqueous solution containing 0.05 - 50 wt.% of dissolved lipopolysaccharide-containing biopolymer material; 0.001-10 wt.% of a surfactant; 0.05 -15 wt.% of solid adsorbent; and at least 50 wt.% of water; b) allowing the adsorbent to adsorb lipopolysaccharides; c) separating the solid adsorbent containing adsorbed lipopolysaccharides from the remaining aqueous solution; and d) recovering the biopolymer material containing a reduced level of lipopolysaccharide from the separated aqueous solution.
patents
